The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preclinical characterization and efficacy of 4R9, a novel immune checkpoint blockade targeting CEACAM1 for cancer therapy.
 
Jae-Chul Lee
No Relationships to Disclose
 
Minkyu Hur
No Relationships to Disclose
 
Hye-Young Park
No Relationships to Disclose
 
EunHee Lee
No Relationships to Disclose
 
Hye In Yum
No Relationships to Disclose
 
Hye-mi Nam
No Relationships to Disclose
 
Mi-Young Oh
No Relationships to Disclose
 
HyungSuk Choi
No Relationships to Disclose
 
Jae-Hwan Kim
No Relationships to Disclose
 
Byoung Chul Cho
Stock and Other Ownership Interests - Theravance
Honoraria - AstraZeneca; Bayer; Champions Oncology; Dizal Pharma; Dong-A ST; Janssen; Mogam Biotechnology Research Institue; MSD; Novartis; Ono Pharmaceutical; Yuhan
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda; Yuhan
Speakers' Bureau - Novartis
Research Funding - AstraZeneca; Bayer; Champions Oncology; Dizal Pharma; Dong-A ST; Janssen; Mogam Biotechnology Research Institue; MSD; Novartis; Ono Pharmaceutical; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology
 
Yang-Mi Lim
No Relationships to Disclose
 
Jonghwa Won
No Relationships to Disclose